---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-005156"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T01:55:57.696765+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Puma Q4 net income $4.2M vs loss; FY loss narrows to $29.1M from $60.0M

## Summary
- Q4 product revenue $51.0M (+2% YoY); total revenue $55.4M including $1.5M license and $2.9M royalty.
- GAAP net income Q4 $4.2M ($0.10 EPS) vs loss of $15.0M ($0.38 loss) in Q4 2020.
- FY 2021 net loss $29.1M ($0.72 loss) vs $60.0M loss ($1.52 loss); non-GAAP adjusted net income $3.5M.
- Cash and securities $82.1M at Dec 31; operating cash flow $20.7M provided in FY 2021 vs $0.8M in FY 2020.
- Key 2022 catalysts: pre-NDA meeting for neratinib HER2-mutant breast cancer, Phase II data in multiple indications.

## SEC filing metadata
- accession: 0001437749-22-005156
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774922005156/0001437749-22-005156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774922005156/pbyi20220228_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-005156
- JSON: https://secwatch.observer/filing/0001437749-22-005156.json
- Plain text: https://secwatch.observer/filing/0001437749-22-005156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.